Lipid-lowering drug therapies: the evidence.
نویسنده
چکیده
Abbreviations: CARE, Cholesterol and Recurrent Events; LIPID, Long-term Intervention with Pravastatin in Ischaemic Disease. Corresponding author: Professor Chris Packard, fax +44 (0)141 211 4322, email [email protected] CAB InternationalPNSProceedings of the Nutrition Society (2000)0029-6651© Nutrition Society 2000 593 59423Cardiovascular disease risk: lifestyle v. drugsC. Packard423 42 2© Nutrition So iety 2000
منابع مشابه
Despite Affordability, Low Utilization of Lipid Lowering Drugs in Iran: Trend Analysis and Benchmarking 2005-2016
Dyslipidemia is responsible for great mortality and morbidity each year. Little data are available on the availability and affordability of Dyslipidemia medications in low and middle incomes countries. In a retrospective time-series study, we examined the utilization pattern and affordability of lipid-lowering medications in Iran as a lower middle-income country. We initially calculated the def...
متن کاملDespite Affordability, Low Utilization of Lipid Lowering Drugs in Iran: Trend Analysis and Benchmarking 2005-2016
Dyslipidemia is responsible for great mortality and morbidity each year. Little data are available on the availability and affordability of Dyslipidemia medications in low and middle incomes countries. In a retrospective time-series study, we examined the utilization pattern and affordability of lipid-lowering medications in Iran as a lower middle-income country. We initially calculated the def...
متن کاملFormulation and Evaluation of Nanocrystals of a Lipid Lowering Agent
Atorvastatin calcium, the lipid lowering agent, is taken as a model drug characterized by poor water solubility and bioavailability. In this study an attempt was made for preparation of nanocrystals using high pressure homogenization. A number of stabilizers were included as well as polymers at different concentrations, and the formulations were homogenized for ten cycles at a pressure of 1000 ...
متن کاملFormulation and Evaluation of Nanocrystals of a Lipid Lowering Agent
Atorvastatin calcium, the lipid lowering agent, is taken as a model drug characterized by poor water solubility and bioavailability. In this study an attempt was made for preparation of nanocrystals using high pressure homogenization. A number of stabilizers were included as well as polymers at different concentrations, and the formulations were homogenized for ten cycles at a pressure of 1000 ...
متن کاملLipid Lowering Activity of Lercanidipine in Hyperlipidemic Rats
The present study was aimed at evaluating the lipid lowering activity of lercanidipine, a calcium channel blocker, in standard diet induced hyperlipidemic rats. Hyperlipidemic rats were divided into different groups and were treated with daily oral dose of lercanidipine and atorvastatin for 7 days. On 8 th day, blood samples were collected and analyzed for serum lipid levels using commercial k...
متن کاملCarvedilol: A Promising Drug Combined with Lipid-lowering Medications for Patients with Hypertension and Heart Failure
Background: Statins frequently cause myopathy especially in combination with fibrates, and physical activity is considered a trigger for the muscle disorder. Elevated plasma levels of creatine kinase (CK), lactate dehydrogenase (LDH) and aldolase, are the main indicators of the severity of myopathy. Carvedilol is commonly used with lipid-lowering drugs in the management of heart failure, hypert...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Proceedings of the Nutrition Society
دوره 59 3 شماره
صفحات -
تاریخ انتشار 2000